Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4.

PMID:
31164413
2.

Paramagnetic Clusters of Mn3(O2CCH3)6(Bpy)2 in Polyacrylamide Nanobeads as a New Design Approach to a T1- T2 Multimodal Magnetic Resonance Imaging Contrast Agent.

Dahanayake V, Pornrungroj C, Pablico-Lansigan M, Hickling WJ, Lyons T, Lah D, Lee Y, Parasido E, Bertke JA, Albanese C, Rodriguez O, Van Keuren E, Stoll SL.

ACS Appl Mater Interfaces. 2019 May 22;11(20):18153-18164. doi: 10.1021/acsami.9b03216. Epub 2019 May 7.

PMID:
30964631
3.

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML.

Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.

4.

Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells.

Tricoli L, Naeem A, Parasido E, Mikhaiel JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkuhle J, Petricoin E, Rodriguez O, Albanese C.

Oncotarget. 2017 Dec 18;9(2):2193-2207. doi: 10.18632/oncotarget.23363. eCollection 2018 Jan 5.

5.

Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M.

Oncotarget. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget.14019.

6.

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.

Waye S, Naeem A, Choudhry MU, Parasido E, Tricoli L, Sivakumar A, Mikhaiel JP, Yenugonda V, Rodriguez OC, Karam SD, Rood BR, Avantaggiati ML, Albanese C.

Aging (Albany NY). 2015 Oct;7(10):854-68.

7.

Thermoresponsive release of viable microfiltrated Circulating Tumor Cells (CTCs) for precision medicine applications.

Ao Z, Parasido E, Rawal S, Williams A, Schlegel R, Liu S, Albanese C, Cote RJ, Agarwal A, Datar RH.

Lab Chip. 2015 Nov 21;15(22):4277-82. doi: 10.1039/c5lc01024a.

8.

The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.

Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, Kallakury B, Dritschilo A, Lynch J, Schlegel R, Rodriguez O, Pestell RG, Avantaggiati ML, Albanese C.

Oncotarget. 2014 Nov 15;5(21):10678-91.

9.

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E.

J Proteome Res. 2014 Jun 6;13(6):2846-55. doi: 10.1021/pr401267m. Epub 2014 May 14.

PMID:
24787230
10.

Individualized therapy for metastatic colorectal cancer.

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C.

J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12. Review.

Supplemental Content

Loading ...
Support Center